TherapeuticsMD, Inc.
TXMD
NASDAQ·Healthcare·Drug Manufacturers - Specialty & Generic·Mkt cap $25.6M
$2.21
▼ -1.34%
P/E
110.50
Mkt Cap
$25.6M
52-Wk Range
$0.99–$2.95
52-Week Range
$0.99 - $2.95
P/E
Fwd P/E
Beta
Div Yield
Avg Vol
Shares Out
Mkt Cap
Price action
Price chart
Up 104.6% over the trailing year
Total returns
Price performance
Total return across standard periods - splits & dividends adjusted by FMP. Periods longer than 1Y show annualized in the tooltip.
Why we rate it this way
The thesis at a glance
Bull and bear case · plain-English context across the five lenses we evaluate.
Bull Case
No bull reasons captured for this rating yet.
Bear Case
1 risk
- Low volatility (beta 0.6).
Growth
Stable outlook
Value
Undervalued - trading well below sector peers
Momentum
Strong
+11.1% over 3m
Quality
Excellent
Solid business
Dividend
None
No dividend
Smart-money signal
Who's buying TXMD right now
Insider Form 4s, 13F institutional filings, and Congressional disclosures - at a glance.
Earnings track record
Recent earnings results
AI-summarized recap of last quarter, plus the surprise on every print.
Next: Nov 17, 2026
AUG 11, 2026
Reported EPS of $0.01 vs -$6.13 consensus (+100.2% surprise). Revenue of $869.0K vs $19.8M expected (-95.6%).
EPS surprise · last 4Q
1 of 1 beats
Estimate
Actual
Q3 26
+100.2%
Revenue trend · last 2Q
—
—
Q1 26
Q2 26
$0
$0
Margins · last 2Q
No margin history available.
Wall Street consensus
Analyst coverage
Live ratings and price targets aggregated across covering analysts.
vs Industry
How TXMD stacks vs Drug Manufacturers - Specialty & Generic
Stock metrics vs industry averages. Green = better than industry.
Industry comparison data unavailable for this stock.